Ticker brief
BHVN
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
13
authors 14d
10
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-22 → 2026-07-01 · now +0.10 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 3 | +0.23 |
| @BioStocks | C | -0.39 | 2 | -0.10 |
| @commonsenseplay | C | +0.11 | 1 | +0.40 |
| @Brad_E_Schulz | C | · | 1 | +0.35 |
| @OptionsFlowBoss | C | · | 1 | +0.45 |
| @semodough | C | -0.75 | 1 | +0.25 |
| @HedgeFundTips | B | -0.75 | 1 | +0.10 |
| @CrweWorld | C | · | 1 | +0.30 |
| @ABBONews | C | · | 1 | +0.25 |
| @USAnt_IDEA | C | -0.65 | 1 | +0.35 |
Recent signals13of 13 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-01 | @OzmosiHealth | +0.10 | Biohaven announced planned Phase 2 epilepsy results in 2H26. | · | tweet ↗ |
| 2026-06-30 | @OzmosiHealth | +0.25 | Biohaven completes enrollment in RISE 3 pivotal focal epilepsy study with Opakalim. | · | tweet ↗ |
| 2026-06-30 | @BioStocks | +0.20 | BHVN completed enrollment in RISE 3 pivotal epilepsy study; data expected 2H26. | · | tweet ↗ |
| 2026-06-29 | @USAnt_IDEA | +0.35 | Korean biotech pipeline roundup cites FDA approvals, trial starts, and results. | · | tweet ↗ |
| 2026-06-29 | @OzmosiHealth | +0.35 | Biohaven says BHV-1300 begins Phase 3 pivotal trial in Graves' Disease. | · | tweet ↗ |
| 2026-06-29 | @ABBONews | +0.25 | Biohaven enrolled first patient in pivotal Phase 3 Graves' disease trial. | · | tweet ↗ |
| 2026-06-29 | @BioStocks | -0.40 | BHVN downgraded to Underperform at BofA with $11 PT. | · | tweet ↗ |
| 2026-06-29 | @CrweWorld | +0.30 | Biohaven's BHV-1300 begins Phase 3 pivotal trial. | · | tweet ↗ |
| 2026-06-26 | @HedgeFundTips | +0.10 | Money-flow list with many tickers; capped first six tickers and mild positive flow implication. | · | tweet ↗ |
| 2026-06-26 | @semodough | +0.25 | BHVN initiated a Phase 3 trial of BHV-1300 for Graves' Disease. | · | tweet ↗ |
| 2026-06-26 | @OptionsFlowBoss | +0.45 | Reports bullish options positioning in BHVN. | · | tweet ↗ |
| 2026-06-22 | @Brad_E_Schulz | +0.35 | Intraday category overview shows Bio/Pharm leading with many stocks up. | · | tweet ↗ |
| 2026-06-22 | @commonsenseplay | +0.40 | Says Biohaven has doubled and hopes followers listened. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.